Trial Profile
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary) ; Infliximab (Primary) ; Mycophenolate mofetil (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMERALD-1
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK
- 20 Jan 2024 Results for safety and efficacy, presented at the 2024 Gastrointestinal Cancers Symposium
- 19 Jan 2024 According to an AstraZeneca Media Release, results from this trial will be presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California (#LBA432).
- 19 Jan 2024 Results presented in an AstraZeneca Media Release.